Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections

Background: The limited armamentarium against multidrug-resistant Gram-negative bacilli led to the development of a new generation of β-lactam/β-lactamase inhibitor combinations (BL/BLI). Objectives: To evaluate the in vitro activity of ceftazidime/avibactam, ceftolozane/tazobactam, meropenem/vaborb...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Helio S. Sader, Mariana Castanheira, Leonard R. Duncan, Rodrigo E. Mendes
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Pseudomonas aeruginosa ceftazidime/avibactam ceftolozane/tazobactam imipenem/relebactam meropenem/vaborbactam Infectious and parasitic diseases RC109-216
Acceso en línea:	https://doaj.org/article/bf9c27dc44894de6a4e64077bcd0288a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:bf9c27dc44894de6a4e64077bcd0288a
record_format	dspace
spelling	oai:doaj.org-article:bf9c27dc44894de6a4e64077bcd0288a2021-11-14T04:31:14ZAntimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections1201-971210.1016/j.ijid.2021.10.022https://doaj.org/article/bf9c27dc44894de6a4e64077bcd0288a2021-12-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S1201971221008092https://doaj.org/toc/1201-9712Background: The limited armamentarium against multidrug-resistant Gram-negative bacilli led to the development of a new generation of β-lactam/β-lactamase inhibitor combinations (BL/BLI). Objectives: To evaluate the in vitro activity of ceftazidime/avibactam, ceftolozane/tazobactam, meropenem/vaborbactam, and imipenem/relebactam against Pseudomonas aeruginosa isolates recovered from patients hospitalized with skin and soft tissue infections (SSTIs) in several countries around the world. Methods: A total of 360 P. aeruginosa isolates were consecutively collected from 47 medical centers located in Western Europe, Eastern Europe, the Asia-Pacific region, and Latin America. Susceptibility testing was performed by broth microdilution method at a monitoring laboratory. EUCAST breakpoints were applied. Results: Ceftazidime/avibactam (98.3% susceptible), ceftolozane/tazobactam (98.6% susceptible), and imipenem/relebactam (98.3% susceptible) were the most active compounds after colistin (100.0% susceptible) and retained activity against isolates nonsusceptible to piperacillin/tazobactam, meropenem, imipenem, and/or ceftazidime. Meropenem-vaborbactam was active against 94.2% of isolates. Ceftazidime/avibactam was the most active BL/BLI against meropenem-nonsusceptible (92.6% susceptible) and imipenem-resistant (93.8% susceptible) isolates, whereas ceftolozane/tazobactam was the most active BL/BLI against piperacillin/tazobactam-resistant (91.1% susceptible) and ceftazidime-resistant (91.7% susceptible) isolates. Conclusions: The recently approved BL/BLIs demonstrated potent activity and broad coverage against contemporary P. aeruginosa isolates from patients with SSTIs.Helio S. SaderMariana CastanheiraLeonard R. DuncanRodrigo E. MendesElsevierarticlePseudomonas aeruginosaceftazidime/avibactamceftolozane/tazobactamimipenem/relebactammeropenem/vaborbactamInfectious and parasitic diseasesRC109-216ENInternational Journal of Infectious Diseases, Vol 113, Iss , Pp 279-281 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Pseudomonas aeruginosa ceftazidime/avibactam ceftolozane/tazobactam imipenem/relebactam meropenem/vaborbactam Infectious and parasitic diseases RC109-216
spellingShingle	Pseudomonas aeruginosa ceftazidime/avibactam ceftolozane/tazobactam imipenem/relebactam meropenem/vaborbactam Infectious and parasitic diseases RC109-216 Helio S. Sader Mariana Castanheira Leonard R. Duncan Rodrigo E. Mendes Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections
description	Background: The limited armamentarium against multidrug-resistant Gram-negative bacilli led to the development of a new generation of β-lactam/β-lactamase inhibitor combinations (BL/BLI). Objectives: To evaluate the in vitro activity of ceftazidime/avibactam, ceftolozane/tazobactam, meropenem/vaborbactam, and imipenem/relebactam against Pseudomonas aeruginosa isolates recovered from patients hospitalized with skin and soft tissue infections (SSTIs) in several countries around the world. Methods: A total of 360 P. aeruginosa isolates were consecutively collected from 47 medical centers located in Western Europe, Eastern Europe, the Asia-Pacific region, and Latin America. Susceptibility testing was performed by broth microdilution method at a monitoring laboratory. EUCAST breakpoints were applied. Results: Ceftazidime/avibactam (98.3% susceptible), ceftolozane/tazobactam (98.6% susceptible), and imipenem/relebactam (98.3% susceptible) were the most active compounds after colistin (100.0% susceptible) and retained activity against isolates nonsusceptible to piperacillin/tazobactam, meropenem, imipenem, and/or ceftazidime. Meropenem-vaborbactam was active against 94.2% of isolates. Ceftazidime/avibactam was the most active BL/BLI against meropenem-nonsusceptible (92.6% susceptible) and imipenem-resistant (93.8% susceptible) isolates, whereas ceftolozane/tazobactam was the most active BL/BLI against piperacillin/tazobactam-resistant (91.1% susceptible) and ceftazidime-resistant (91.7% susceptible) isolates. Conclusions: The recently approved BL/BLIs demonstrated potent activity and broad coverage against contemporary P. aeruginosa isolates from patients with SSTIs.
format	article
author	Helio S. Sader Mariana Castanheira Leonard R. Duncan Rodrigo E. Mendes
author_facet	Helio S. Sader Mariana Castanheira Leonard R. Duncan Rodrigo E. Mendes
author_sort	Helio S. Sader
title	Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections
title_short	Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections
title_full	Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections
title_fullStr	Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections
title_full_unstemmed	Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections
title_sort	antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against pseudomonas aeruginosa from patients with skin and soft tissue infections
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/bf9c27dc44894de6a4e64077bcd0288a
work_keys_str_mv	AT heliossader antimicrobialactivitiesofceftazidimeavibactamceftolozanetazobactamimipenemrelebactammeropenemvaborbactamandcomparatorsagainstpseudomonasaeruginosafrompatientswithskinandsofttissueinfections AT marianacastanheira antimicrobialactivitiesofceftazidimeavibactamceftolozanetazobactamimipenemrelebactammeropenemvaborbactamandcomparatorsagainstpseudomonasaeruginosafrompatientswithskinandsofttissueinfections AT leonardrduncan antimicrobialactivitiesofceftazidimeavibactamceftolozanetazobactamimipenemrelebactammeropenemvaborbactamandcomparatorsagainstpseudomonasaeruginosafrompatientswithskinandsofttissueinfections AT rodrigoemendes antimicrobialactivitiesofceftazidimeavibactamceftolozanetazobactamimipenemrelebactammeropenemvaborbactamandcomparatorsagainstpseudomonasaeruginosafrompatientswithskinandsofttissueinfections
_version_	1718429983279415296

Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections

Ejemplares similares